Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.9K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.9K
The Proteasome02:18

The Proteasome

10.1K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.1K
The Proteasome01:13

The Proteasome

1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Protein-protein Interfaces02:04

Protein-protein Interfaces

14.4K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antibody reveals conformational latch regulating dimerization in β- and γ-herpesvirus proteases.

Nature communications·2026
Same author

A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention.

ACS central science·2026
Same author

Structural Basis of Serine Protease Inhibition by Antibodies from Biased Fab Phage-Display Libraries.

bioRxiv : the preprint server for biology·2026
Same author

Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models.

Journal of medicinal chemistry·2026
Same author

Precision Labeling of Native Antibodies with Lock Coupling.

Journal of the American Chemical Society·2025
Same author

Antibody Reveals Conformational Latch Controlling Herpesvirus Proteases.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: Jan 17, 2026

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
10:50

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

16.9K

Identifying protease-activated targets and exploring therapeutic applications.

Deokhee Kang1, Charles S Craik1

  • 1Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.

Expert Opinion on Therapeutic Targets
|September 18, 2025
PubMed
Summary

Advances in protease research reveal new therapeutic targets. Understanding disease-related proteases and their substrates can drive the development of novel, amplified therapeutic interventions.

Keywords:
Cancer therapeuticsProdrugsProteasesconditional activationendogenous substratesmass spectrometrypeptide substrate profilingtumor microenvironment

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation
19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

9.7K

Related Experiment Videos

Last Updated: Jan 17, 2026

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics
10:50

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

16.9K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.0K
Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation
19:23

Use of Recombinant Fusion Proteins in a Fluorescent Protease Assay Platform and Their In-gel Renaturation

Published on: January 16, 2019

9.7K

Area of Science:

  • Biochemistry and Molecular Biology
  • Enzymology
  • Proteomics

Background:

  • Proteases are enzymes crucial for protein regulation and signaling.
  • Traditionally viewed as degradative, proteases have diverse roles in diseases like cancer and viral infections.
  • High-throughput technologies enable proteome-wide identification of protease substrates, offering therapeutic targets.

Purpose of the Study:

  • To highlight the importance of understanding disease-related proteases in their biological contexts.
  • To explore the potential of protease-activated therapeutic strategies.
  • To bridge advances in substrate identification with peptide-level techniques for drug development.

Main Methods:

  • Proteome-wide identification of protease substrates using mass spectrometry.
  • Development and application of peptide-level chemical libraries.
  • Harnessing proteolytic activity for conditional therapeutic activation.

Main Results:

  • Identification of numerous potential therapeutic targets through large-scale proteomic approaches.
  • Demonstration of challenges like enzymatic redundancy and substrate promiscuity in early inhibitor development.
  • Emerging success in using proteolytic activation for conditional drug delivery.

Conclusions:

  • Identifying disease-associated protease substrates is key to deeper biological insights.
  • Technological advances facilitate the discovery of novel protease-substrate interactions.
  • Combining substrate identification with peptide-level approaches can lead to efficient therapeutics with amplified effects.